Senti Biosciences, Inc. (SNTI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments, including: | 35,900 | 98,600 | 889 | |||
| Cash and cash equivalent | 35,926 | 57,621 | 889 | |||
| Short-term investments | 40,942 | |||||
| Other undisclosed cash, cash equivalents, and short-term investments | (26) | 37 | ||||
| Receivables | 626 | |||||
| Prepaid expense | 2,546 | 1,871 | 408 | |||
| Deposits current assets | 42 | 1,418 | ||||
| Other current assets | 195 | 101 | ||||
| Other undisclosed current assets | 32,517 | (37) | ||||
| Total current assets: | 71,200 | 102,579 | 1,297 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 16,274 | 18,418 | ||||
| Property, plant and equipment | 25,338 | 56,136 | ||||
| Long-term investments and receivables | 1,119 | |||||
| Accounts and financing receivable, after allowance for credit loss | 1,119 | |||||
| Prepaid expense | 151 | |||||
| Asset, held-in-trust | 230,009 | |||||
| Other noncurrent assets | 215 | 293 | ||||
| Other undisclosed noncurrent assets | 5,338 | 3,366 | ||||
| Total noncurrent assets: | 48,284 | 78,213 | 230,159 | |||
| TOTAL ASSETS: | 119,484 | 180,792 | 231,457 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 3,622 | 13,381 | 3,243 | |||
| Taxes payable | ✕ | ✕ | ✕ | 164 | ||
| Accounts payable | 1,250 | 2,267 | ||||
| Accrued liabilities | 2,372 | 11,114 | 3,079 | |||
| Deferred revenue | 799 | |||||
| Debt | 97 | |||||
| Disposal group, including discontinued operation | 243 | |||||
| Other undisclosed current liabilities | 8,710 | 3,873 | 40 | |||
| Total current liabilities: | 12,672 | 18,053 | 3,282 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 39,889 | 35,330 | ||||
| Other liabilities | ||||||
| Operating lease, liability | 33,538 | 35,103 | ||||
| Business combination, contingent consideration, liability | 20 | 227 | ||||
| Derivative instruments and hedges, liabilities | 6,331 | |||||
| Other undisclosed noncurrent liabilities | 10 | 146 | 7,050 | |||
| Total noncurrent liabilities: | 39,899 | 35,476 | 7,050 | |||
| Total liabilities: | 52,571 | 53,529 | 10,332 | |||
| Temporary equity, including noncontrolling interest | 230,000 | |||||
| Equity | ||||||
| Equity, attributable to parent, including: | 66,913 | 127,263 | (8,876) | |||
| Common stock | 5 | 4 | ||||
| Additional paid in capital | 311,252 | 300,544 | ||||
| Accumulated other comprehensive income | 1 | |||||
| Accumulated deficit | (244,344) | (173,286) | (8,876) | |||
| Other undisclosed equity, attributable to parent | 1 | |||||
| Total equity: | 66,913 | 127,263 | (8,876) | |||
| TOTAL LIABILITIES AND EQUITY: | 119,484 | 180,792 | 231,457 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 2,561 | 4,286 | |||
| Sublease income | 2,323 | ||||
| Cost of revenue (Cost of Product and Service Sold) | |||||
| Gross profit: | 2,561 | 4,286 | |||
| Operating expenses | (95,288) | (74,915) | |||
| Other undisclosed operating loss | |||||
| Operating loss: | (92,727) | (70,629) | |||
| Nonoperating income | 9,321 | 12,419 | |||
| Interest and debt expense | 1,289 | ||||
| Net loss: | (83,406) | (56,921) | |||
| Other undisclosed net income (loss) attributable to parent | 12,348 | (1,289) | |||
| Net loss attributable to parent: | (71,058) | (58,210) | |||
| Preferred stock dividends and other adjustments | |||||
| Net loss available to common stockholders, diluted: | (71,058) | (58,210) | |||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (83,406) | (56,921) | |||
| Other comprehensive loss | (1) | ||||
| Comprehensive loss: | (83,406) | (56,922) | |||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 12,347 | (1,287) | |||
| Comprehensive loss, net of tax, attributable to parent: | (71,059) | (58,209) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.